+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase Not Applicable
Age: 18Years - 50Years
FEMALE
ID07820670

Comparing Rivaroxaban and Enoxaparin for Blood Clot Prevention After Elective Cesarean Section A Randomized Open-Label Trial

Led by Wolfson Medical Center · Updated on 2026-09-15

62

Participants Needed

1

Research Sites

26 weeks

Total Duration

AI-Summary

What This Trial Is About

Pregnancy and the postpartum period increase the risk of venous thromboembolism VTE, especially after cesarean section. Researchers are studying and comparing the anticoagulant effects of rivaroxaban, a direct oral anticoagulant taken once daily by mouth, with enoxaparin, a low-molecular-weight heparin given by daily injection. The goal is to evaluate their laboratory effects on blood clotting parameters in women who need short-term thromboprophylaxis after elective cesarean delivery during their hospital stay. Participants are randomly assigned to receive either rivaroxaban 10 mg by mouth once daily or enoxaparin 40 mg by subcutaneous injection once daily. Treatment starts at least 12 hours after cesarean delivery and 6 hours after spinal anesthesia, continuing until hospital discharge. Blood samples are taken on postoperative day 2 before and about 3 hours after dosing to measure thrombin generation, anti-Xa activity, and drug levels. Participants also complete a satisfaction questionnaire before discharge. Safety follow-up is conducted by telephone 2 days after discharge and again at 6 weeks postpartum. During the study, participants will have blood tests to assess clotting function and drug activity, including measurements such as endogenous thrombin potential, lag time, and peak thrombin. The study tracks adverse events including bleeding and VTE from enrollment through 6 weeks postpartum. Participant satisfaction with treatment is also recorded. The total participation includes the hospital stay for treatment and follow-up calls up to 6 weeks after delivery to monitor safety and outcomes.

CONDITIONS

Brief Title

Rivaroxaban vs Enoxaparin After Cesarean Section: Laboratory Thromboprophylaxis Outcomes

Research Team

O

Or Marom, MD

H

Hagit Eisenberg, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here